in its filing to the exchanges informed that the company has received final approval from the USFDA to market Betamethasone Dipropionate Cream and Amlodipine & Atorvastatin Tablets.
The company will manufacture drugs at its formulations manufacturing facility in SEZ, Ahmedabad, it said in a press note to the exchanges on Friday.
"Betamethasone Dipropionate Cream is a strong corticosteroid and is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). It reduces the swelling, itching, and redness that can occur in these types of conditions," the company added.
Further, the company will market Amlodipine and Atorvastatin Tablets USP (US RLD-Caduet) in the strengths of 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg.
"This combination product contains two active ingredients-amlodipine and atorvastatin. Amlodipine reduces blood pressure and the workload on the heart by relaxing the walls of the blood vessels. It is used to lower blood pressure and to treat angina (chest pain). Atorvastatin is used in combination with diet and exercise to treat high cholesterol. It works by blocking an enzyme that is needed to make cholesterol in the body," Cadila added in the press note.
Cadila Healthcare Ltd's share price ended at Rs347.55 on Friday, down by Rs2.2 or 0.63%, from its previous close of Rs349.75 on the BSE.
The scrip opened at Rs351 and touched a high and low of Rs352.55 and Rs347.55, respectively. A total of, 9,30,385 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs35,749.09cr.